← Search & browse all drugs
CARDIOVASCULAR SYSTEM › ANTIHYPERTENSIVES › OTHER ANTIHYPERTENSIVES › Antihypertensives for pulmonary arterial hypertension
ambrisentan and tadalafil
C02KX52
Forms & Strengths
- 10mg ambrisentan and 20mg tadalafil tablets
- 10mg ambrisentan and 40mg tadalafil tablets
Adult Dosing
- Initial dose: 10mg ambrisentan and 20mg tadalafil once daily
- Titrate to 10mg ambrisentan and 40mg tadalafil once daily as needed
Pediatric Dosing
- Not established for patients under 18 years old
Indications
- Treatment of pulmonary arterial hypertension (PAH) to improve exercise ability
- Reducing the risk of disease progression
Mechanism of Action
- Ambrisentan: endothelin receptor antagonist
- Tadalafil: phosphodiesterase type 5 inhibitor increasing cyclic GMP
Contraindications
- Hypersensitivity to ambrisentan, tadalafil, or any component
- Concomitant use with nitrates, riociguat, or guanylate cyclase stimulators
- Pregnancy, as it may cause fetal harm
Adverse Reactions
- Headache
- Nausea
- Dizziness
- Flushing
- Nasal congestion
- Peripheral edema
Drug Interactions
- Increased risk of hypotension with concomitant nitrates, alpha-blockers, or PDE5 inhibitors
- Concomitant use with strong CYP3A inhibitors may increase ambrisentan exposure
- Bosentan may increase risk of liver enzyme elevation when used with ambrisentan
Curated Content: Needs Vetting Before Put to Clinical Use